Abstract. Four heart hormones, namely atrial natriuretic peptide (ANP), long-acting natriuretic peptide (LANP),
these pathways and their crosstalk is inhibited by these peptide hormones. They enter the nucleus of cancer cells where they inhibit the proto-oncogenes c-FOS (by up to 82%) and c-JUN (by up to 61%). Conclusion: These multiple kinase inhibitors have both adjunct and primary anticancer effects.The amino acid sequences of atrial natriuretic peptide (ANP) and the ANP prohormone from which it is derived were determined in 1984 (1-8). ANP has anticancer effects both in vitro (9-20) and in vivo (21, 22). ANP eliminates 80% of human pancreatic carcinomas (21) and 43% of human small cell lung carcinomas growing in mice (22). Recently ANP has been used for 3 hours intravenously as an adjunct after 'curative' lung cancer surgery, which resulted in a 2-year relapse-free survival of 91% (77 patients) versus 75% (p=0.018) in 390 patients treated with surgery alone (23). When peer-matched patients (77 each) were analyzed by propensity score matching, the 2-year relapse-free survival was 91% for those treated with ANP versus 67% for those treated with surgery alone (p=0.0013) (23). This study would suggest that adding ANP after surgery as an adjunct may be helpful in preventing recurrence after surgery (23). The present review focuses on the mechanism of how ANP and other cardiac peptide hormones eliminate primary carcinomas in vivo and metastatic lesions (21, 22).
ANPANP prohormone can produce four hormones, one of which is ANP. The ANP prohormone gene encoding the synthesis of the 126 amino acid ANP prohormone consists of three exons sequences, separated by two introns, which encode for a mature mRNA transcript approximately 900 bases long (3,(24)(25)(26)(27). Translation of the human ANP prohormone mRNA results
5693